Health

Molina Healthcare's CFO lays out a path to $9.50 EPS in 2027, on $4 of fixes not yet earned

Molina's finance chief added $4 of "embedded earnings" to a $5.25 floor for 2027, assuming no recovery at all in Medicaid margins. Guidance, and the test of each dollar, arrives in February.

Vincent JiangVincent Jiangthree-minute read
Share
Molina Healthcare logo
1 / 6Slide 1 of 6
Molina Healthcare, whose CFO Mark Keim laid out a $9.50 adjusted EPS framework for 2027 at the UBS Global Healthcare Conference.

A $9.50 bridge whose biggest plank is losing money

At UBS's Global Healthcare Conference on November 9, Molina Healthcare+1.41% — Molina Healthcare, up 1.41 percent today (NYSE: MOH) chief financial officer Mark Keim gave investors the insurer's first full arithmetic for 2027: adjusted earnings of at least $9.50 a share, 81% above the 2026 floor of at least $5.25 1.

The largest single piece is the $6 billion Florida CMS Kids contract, a new Medicaid program Molina has run for about a month and expects to show a 99% medical loss ratio, the share of premium spent on care, and a 5% pretax loss in the fourth quarter before break-even next year 1.

A November 6 securities filing had re-anchored 2026 at floors of $2.38 GAAP and $5.25 adjusted 2. The floor sits under a bruised stock: third-quarter net income fell 52% to $38 million and shares dropped 4.4% on the October 21 report, which The Inference covered at the time 34.

Two of the four dollars are last year's losses

Keim splits the $4 of "embedded earnings" three ways: $1.50 as Florida reaches break-even, $1 from exiting the traditional Medicare Advantage drug plan, and $1.50 from administrative efficiency as premium revenue grows from about $42 billion to $45 billion 1. Molina's own 2026 guidance already carries matching losses: $1.50 a share from the Florida implementation and $1 from the Medicare product being exited 3. Two of the four dollars are the arithmetic of not repeating 2026 2. The filing's safe-harbor paragraph lists "embedded" among its forward-looking words 2.

Molina's 2027 framework: a $5.25 floor plus $4 of embedded earnings

Only the $5.25 floor is guidance; the $4 above it are fixes management expects

  • Estimate
$0$2$4$62026 adjusted EPS floor$5.25Florida breakeven$1.5One month old; 99% MCR and 5% pretax loss due in Q4Medicare exit$1Admin leverage$1.5
Data
Value
2026 adjusted EPS floor (estimate)$5.25
Florida breakeven (estimate)$1.5
Medicare exit (estimate)$1
Admin leverage (estimate)$1.5
Per-share contributions to 2027 adjusted EPS, per CFO Mark Keim's framework at the UBS Global Healthcare Conference, November 9, 2026; not formal guidance.1,2

What the framework refuses to assume

The build asks nothing of Medicaid: its 92.6% loss ratio stays put, rates rise about 6% against medical trend of 5.5% to 6%, most markets stay about 300 basis points underfunded, and 6% of members are assumed to leave under OB3 eligibility changes including work requirements 1.

The Marketplace flip from a $0.75 per-share loss to break-even is bought by retreating from 13 or 14 states to about six, giving up roughly $1 billion of 2027 revenue in a market where benchmark silver premiums are up 13% by KFF's count 15.

Ohio is an exit with a name: Molina will not sell Affordable Care Act plans there in 2027, half of a two-insurer withdrawal touching about 54,000 people 6. Marketplace membership has already fallen from 655,000 to 267,000 this year 3.

February prices the promises

Keim's defense is that the framework needs no Medicaid turnaround: any loss-ratio improvement is upside, and chief executive Joseph Zubretsky has said the company is "likely observing the beginning of the turn in Medicaid margins" 13. None of it is audited, and Florida has yet to earn a dollar. Formal guidance comes in February, when Molina revisits the 6% membership assumption; the remaining $5 of embedded earnings is penciled in for 2028 and 2029 1. The floor is real money; the four dollars are promises with a February deadline.

Get Health by email, free

AI in medicine, pharma and biotech. In our daily email, every weekday.

Loading MOH

Reader comments

0 comments

    More in Health

    All in this topic →

    Health

    Hims & Hers grew revenue 49% to $890 million, lost $33 million, and cut its 2026 profit outlook a third time

    Revenue grew 49% and the quarter still lost money, because selling Lilly's and Novo's branded weight-loss drugs books the full price without keeping it. Hims shareholders are paying for the pivot; Lilly gains a channel it barely needs.

    Health

    ACP licenses its guidelines to OpenEvidence for an undisclosed price

    The largest US medical society's guidance moves into a free, ad-funded AI valued at $15 billion, and neither side named the fee. For listed readers, the test is Wolters Kluwer's UpToDate renewals at February 2027 results.

    Health

    FDA orders NAION vision-loss warning on every GLP-1 label; Novo Nordisk up 2.65%, Eli Lilly up 4.28%

    The FDA's class-wide vision-loss warning on the world's biggest drug franchise rests on ten probable cases against five among placebo patients; Novo Nordisk and Eli Lilly rose on the news, and hundreds of blindness suits now hold a federal exhibit.

    Health

    Eli Lilly will file its obesity pill Foundayo for sleep apnea after a 44% cut in severity

    A 43.8% cut in breathing interruptions gives Lilly's pill a shot at a diagnosed-disease budget, and the company commits to an FDA filing by year-end. Novo Nordisk's rival outcomes strategy failed at the same heart conference.

    Health

    Novo Nordisk's ziltivekimab cut inflammation 76% but not heart outcomes; Novartis's pelacarsen failed too

    Published in the New England Journal of Medicine beside Novartis's identical pelacarsen null, the full results show how far a record biomarker win sits from a clinical outcome. The bill already runs from Novo's DKK 4.6 billion write-down to Ionis, down 28% on Monday.

    Health

    Volta's Callisto robot automates sample prep for Roche's AXELIOS 1, the $750,000 challenger to Illumina

    A venture-backed Boston startup quietly wired its walk-away sample-prep robot into Roche's new AXELIOS 1 sequencer. The switch cost that protects Illumina's 70% grip is a wall of workflow apps, and Volta just handed the challenger a load-bearing one.

    Get the newsletter

    The day's AI and market news, in your inbox every weekday.